Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, slows the progression of kidney function decline in patients with glomerular disease, according to an exploratory subgroup analysis of the phase 3 FIND-CKD trial presented at the 2026 European Renal Association Congress and published in JAMA. Researchers found that the drug reduced albuminuria by 42% at 12 months and lowered the risk of kidney failure compared to a placebo in adults with nondiabetic chronic kidney disease.
How does finerenone impact glomerular disease progression?
The FIND-CKD trial, led by Brendon Neuen, MBBS, PhD, demonstrated that patients receiving finerenone experienced a slower decline in estimated glomerular filtration rate (eGFR) than those on a placebo. Over a 32-month observation period, the finerenone group saw a total eGFR slope of –3.50 mL/min/1.73 m2/year, while the placebo group reached –4.23 mL/min/1.73 m2/year. These results suggest that targeting mineralocorticoid receptor overactivation may provide a specific renoprotective pathway for patients with glomerular disorders, which are a leading global cause of kidney failure.
The FIND-CKD study cohort included 1,584 participants across 24 countries. Of these, 903 individuals—or 57% of the total study population—had investigator-reported glomerular disease.
What specific glomerular conditions were studied?
The trial’s subgroup analysis included a diverse range of glomerular subtypes, providing insight into how the treatment performs across different diagnoses. According to the data reported by Dr. Neuen and colleagues, the breakdown of the 903 participants with glomerular disease included:
- Immunoglobulin A (IgA) nephropathy: 46.1% (n=416)
- Focal segmental glomerulosclerosis: 23.8% (n=215)
- Membranous nephropathy: 10.0% (n=90)
The study population was notably diverse, with a mean age of 51.1 years and 69.1% of the cohort identifying as Asian. This geographic and clinical spread adds weight to the findings, as IgA nephropathy is particularly prevalent in Asian populations.
Why the shift toward finerenone matters for clinical practice
Prior to these findings, the renoprotective benefits of finerenone were primarily established in patients with type 2 diabetes and chronic kidney disease (CKD). By demonstrating efficacy in patients without diabetes, the FIND-CKD trial expands the potential clinical utility of the drug. The study indicates that finerenone not only preserves eGFR but also reduces the risk of kidney-cardiovascular composite outcomes, including heart failure hospitalizations and death due to cardiovascular disease.
Monitoring albuminuria levels remains a critical clinical biomarker. The 42% reduction observed at 12 months serves as a proxy for long-term kidney health, suggesting that clinicians should track these levels closely when initiating therapy.
Frequently Asked Questions
Is finerenone effective for all types of kidney disease?
The FIND-CKD trial specifically analyzed patients with nondiabetic chronic kidney disease and investigator-reported glomerular disease. While results are promising for these groups, clinical application should be discussed with a nephrologist based on individual patient history.
What is the primary benefit of finerenone for glomerular disease?
According to the JAMA findings, the primary benefit is a significant slowing of the eGFR decline rate and a reduced risk of progression to kidney failure or a 40% or greater decline in kidney function.
How does this study compare to previous research?
Previous studies focused heavily on patients with type 2 diabetes. This analysis provides the necessary data to show that the protective effects of finerenone extend to nondiabetic patients suffering from glomerular-specific damage.
Are you a healthcare provider or a patient interested in the latest developments in nephrology? Subscribe to our newsletter for monthly updates on clinical trials and renal care breakthroughs.
